
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter D - Drugs for Human Use
#### PART 314 - APPLICATIONS FOR FDA APPROVAL TO MARKET A NEW DRUG
##### Subpart C - Abbreviated Applications
###### ยง 314.94 Content and format of an ANDA.
####### Untimely filing of patent information.

(vi)(A) If a patent on the listed drug is issued and the holder of the approved NDA for the listed drug does not file with FDA the required information on the patent within 30 days of issuance of the patent, an applicant who submitted an ANDA for that drug that contained an appropriate patent certification or statement before the submission of the patent information is not required to submit a patent certification or statement to address the patent or patent information that is late-listed with respect to the pending ANDA. Except as provided in ยง 314.53(f)(1), an NDA holder's amendment to the description of the approved method(s) of use claimed by the patent will be considered untimely filing of patent information unless:
